Novartis/$NVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novartis

Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Ticker

$NVS
Sector

Primary listing

NYSE

Employees

75,883

Headquarters

Basel, Switzerland

Novartis Metrics

BasicAdvanced
$245B
18.47
$6.85
0.53
$2.60
2.05%

What the Analysts think about Novartis

Analyst ratings (Buy, Hold, Sell) for Novartis stock.

Bulls say / Bears say

Novartis raised its full-year 2025 core operating income growth forecast to a low-teens percentage after Q2 adjusted operating income rose 20% to $5.9 billion and sales climbed 12% to $14 billion, underpinned by strong demand for Kisqali, Kesimpta and Entresto. (Reuters)
Phase 3 data presented in late August showed that BAF312 reduced three-month confirmed disability progression in secondary progressive multiple sclerosis by 21% versus placebo, supporting analysts’ forecast of up to $3 billion in peak annual sales. (Reuters)
FDA approved Kisqali in March for first-line treatment of HR+/HER2- negative advanced breast cancer after trial results showed a 44% reduction in the risk of disease progression or death versus letrozole alone, positioning Novartis to challenge Pfizer’s Ibrance in a market exceeding $2 billion. (Reuters)
Novartis suffered a legal setback when a U.S. court denied its injunction to block a generic version of heart failure drug Entresto, with generic entry expected in H2 2025 to weigh on sales growth. (Reuters)
Beovu’s launch was initially sluggish after regulators in the U.S. and Europe issued safety warnings over rare cases of retinal vasculitis and vascular occlusion, prompting an external safety review that has delayed uptake. (Reuters)
Novartis pushed back completion of a large UK outcomes study for cholesterol drug Leqvio to 2026 due to COVID-19 recruitment delays, deferring key efficacy data needed for broader adoption. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

Novartis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novartis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVS

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs